Loading...
Market
Story
Merck's HPV Vaccine for Men Approved by China’s Drug Regulator for Ages 9-26, First of Its Kind
Jan 8, 2025, 04:50 AM
China's drug regulator has approved Merck's human papillomavirus (HPV) vaccine for men, marking a significant expansion for the U.S. pharmaceutical company in an emerging market. The vaccine is specifically authorized for males aged 9 to 26 and is the first of its kind in China. This approval comes after a decline in demand among women for the vaccine, which had previously surged. Merck's announcement, made via its Chinese subsidiary, MSD, highlights the potential for growth in a new demographic following the approval by China's medical products administration.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
$500 million to $1 billion • 25%
Less than $500 million • 25%
Decrease • 25%
Other • 25%
Remain the same • 25%
Increase • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
More than 3 million • 25%
Less than 1 million • 25%
1-2 million • 25%
2-3 million • 25%
25% to 50% • 25%
More than 75% • 25%
Less than 25% • 25%
50% to 75% • 25%
10% to 15% • 25%
More than 15% • 25%
5% to 10% • 25%
Less than 5% • 25%
Neither gains market share • 25%
Both gain equally • 25%
Novo Nordisk gains market share • 25%
Eli Lilly gains market share • 25%
20% to 40% • 25%
More than 60% • 25%
41% to 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
More than 60% • 25%
40% to 60% • 25%
Less than 20% • 25%